Formula I Compounds Targeting 3CLPro for Coronavirus Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral treatments lack effective solutions for coronavirus infections, particularly for SARS-CoV-2, due to the conservation of critical residues in the 3CLPro enzyme, making it a challenging target for drug design.
Innovation Solution
Development of compounds with the structure of Formula (I), which inhibit the protease activity of 3CLPro, showing better inhibitory activity with higher numbers of galloyl moieties, and are effective in treating coronavirus infections by administering them to subjects, either orally or through inhalation, to alleviate symptoms caused by SARS-CoV-2 and other coronavirus strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds with higher numbers of galloyl moieties are used, then inhibitory activity against 3CLPro is improved, but molecular complexity increases
Solution Approach 1:
The compound is segmented into multiple galloyl moieties (2-35 units) attached to a core structure, allowing incremental enhancement of inhibitory activity while maintaining a modular design that facilitates synthesis and optimization
Solution Approach 2:
The number of galloyl moieties is varied as a key parameter (2-35 units) to optimize inhibitory activity against 3CLPro, demonstrating how changing molecular parameters can improve therapeutic efficacy while managing complexity through systematic variation
2Reliability
If compounds of Formula (I) are administered to treat coronavirus infection, then viral replication is inhibited, but potential off-target effects may occur
Solution Approach 1:
The compound exhibits selective action specifically at the 3CLPro protease target site, with the galloyl moieties designed to interact locally with the active site of the protease, thereby achieving viral replication inhibition while minimizing off-target effects through localized molecular recognition
3Reliability
If compounds with multiple galloyl moieties are synthesized, then protease inhibition is enhanced, but manufacturing complexity increases
Solution Approach 1:
The compound is constructed from repeatable galloyl units that can be systematically assembled, allowing for standardized synthesis approaches that reduce manufacturing complexity despite the presence of multiple moieties (2-35 units)
Solution Approach 2:
The number of galloyl moieties is controlled within a defined range (2-35) to balance protease inhibition efficacy with manufacturability, demonstrating how parameter optimization can simultaneously address therapeutic effectiveness and production feasibility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds successfully inhibit SARS-CoV-2 replication and show presence in pulmonary tissues, demonstrating potential in treating coronavirus infections by effectively targeting the 3CLPro enzyme, thereby alleviating conditions caused by coronavirus infections.
Implementation Method 1
exemplary compounds having the structure of Formula (I) described herein successfully inhibited the protease activity of 3CLPro of SARS-CoV-2
Data Source
AI summary
A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I):or a pharmaceutically acceptable salt thereof.